FindTrial
Sign In

Development and Application of a Clinical Risk-Prediction Model for Immune Checkpoint Inhibitor-Related Pneumonitis in Patients with Gastrointestinal Cancer

Development and Application of a Clinical Risk-Prediction Model for Immune Checkpoint Inhibitor-Related Pneumonitis in Patients with Gastrointestinal Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400089775
Enrollment
Unknown
Registered
2024-09-14
Start date
2023-08-09
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

checkpoint inhibitor pneumonitis

Interventions

Observation group:None

Sponsors

Beijing University Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: age >18 years; pathologic diagnosis of malignancy; treatment with ICIs.

Exclusion criteria

Exclusion criteria: Patients with a definite other cause of pneumonia (e.g., radiation pneumonitis, neococcal pneumonia, and tumor-infiltrating lungs); incomplete case information >20%.

Design outcomes

Primary

MeasureTime frame
CIP occurs;No CIP;—

Countries

China

Contacts

Public ContactZhang Liyan

Peking University Cancer Hospital

zhangliyand@126.com+86 182 1018 7087

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026